HIV-1 vaccine development: Progress and prospects

Current Infectious Disease Reports

Volumn 9, Issue 1, 2007, Pages 71-75

  Thorner, Anna R ^b   Barouch, Dan H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS 1 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; LIVE VACCINE; NEF PROTEIN; POL PROTEIN; RECOMBINANT GLYCOPROTEIN GP 120; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ADENOVIRUS 5; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; IMMUNOREGULATION; INFECTION PREVENTION; MONKEY DISEASE; NONHUMAN; POXVIRUS; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 33846964896     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0025-0     Document Type: Review

References (50)

1. Borrow P, Lewicki H, Hahn BH, et al.: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110.
2. Pantaleo G, Demarest JF, Soudeyns H, et al.: Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994, 370:463-467.
3. Musey L, Hughes J, Schacker T, et al.: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997, 337:1267-1274.
4. Schmitz JE, Kuroda MJ, Santra S, et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
5. Allen TM, O'Connor DH, Jing P, et al.: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000, 407:386-390.
6. Evans DT, O'Connor DH, Jing P, et al.: Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med 1999, 5:1270-1276.
7. Barouch DH, Kunstman J, Kuroda MJ, et al.: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002, 415:335-339.
8. Price DA, Goulder PJ, Klenerman P, et al.: Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A 1997, 94:1890-1895.
9. Moore CB, John M, James IR, et al.: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296:1439-1443.
10. Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
11. Douek DC, Brenchley JM, Betts MR, et al.: HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-98.
12. Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003, 100:4144-4149.
13. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
14. Chen B, Vogan EM, Gong H, et al.: Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433:834-841.
15. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
16. Wyatt R, Kwong PD, Desjardins E, et al.: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393:705-711.
17. Haynes BF, Fleming J, St Clair EW, et al.: Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
18. Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000, 6:200-206.
19. Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
20. Veazey RS, DeMaria M, Chalifoux LV, et al.: Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
21. Mattapallil JJ, Douek DC, Hill B, et al.: Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1097.
22. Li Q, Duan L, Estes JD, et al.: Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148-1152.
23. Mattapallil JJ, Douek DC, Buckler-White A, et al.: Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 2006, 203:1533-1541.
24. Letvin NL, Mascola JR, Sun Y, et al.: Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006, 312:1530-1533.
25. Daniel MD, Kirchhoff F, Czajak SC, et al.: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941.
26. Baba TW, Jeong YS, Pennick D, et al.: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995, 267:1820-1825.
27. Learmont JC, Geczy AF, Mills J, et al.: Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 1999, 340:1715-1722.
28. Murphey-Corb M, Martin LN, Davison-Fairburn B, et al.: A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989, 246:1293-1297.
29. Stott EJ: Anti-cell antibody in macaques. Nature 1991, 353:393.
30. Kahn JO, Cherng DW, Mayer K, et al.: Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 10(6)/L CD4 cell counts: A randomized controlled trial. JAMA 2000, 284:2193-2202.
31. Flynn NM, Forthal DN, Harro CD, et al.: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
32. Barouch DH, Santra S, Schmitz JE, et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290:486-492.
33. Amara RR, Villinger F, Altman JD, et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
34. Shiver JW, Fu TM, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335.
35. Pilcher CD, Fiscus SA, Nguyen TQ, et al.: Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005, 352:1873-1883.
36. Sumida SM, McKay PF, Truitt DM, et al.: Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 2004, 114:1334-1342.
37. Otten G, Schaefer M, Doe B, et al.: Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22:2489-2493.
38. Shiver JW, Emini EA: Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004, 55:355-372.
39. Casimiro DR, Chen L, Fu TM, et al.: Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77:6305-6313.
40. Vogels R, Zuijdgeest D, van Rijnsoever R, et al.: Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003, 77:8263-8271.
41. Kostense S, Koudstaal W, Sprangers M, et al.: Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004, 18:1213-1216.
42. Sumida SM, Truitt DM, Lemckert AA, et al.: Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005, 174:7179-7185.
43. Barouch DH, Pau MG, Custers JH, et al.: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172:6290-6297.
44. Lemckert AA, Sumida SM, Holterman L, et al.: Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005, 79:9694-9701.
45. Farina SF, Gao GP, Xiang ZQ, et al.: Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001, 75:11603-11613.
46. Fitzgerald JC, Gao GP, Reyes-Sandoval A, et al.: A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003, 170:1416-1422.
47. Nanda A, Lynch DM, Goudsmit J, et al.: Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 2005, 79:14161-14168.
48. Roberts DM, Nanda A, Havenga MJ, et al.: Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441:239-243.
49. Klausner RD, Fauci AS, Corey L, et al.: Medicine. The need for a global HIV vaccine enterprise. Science 2003, 300:2036-2039.
50. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2005, 2:e25.